Exploiting protease activation for therapy

被引:18
作者
Bleuez, Chloe [1 ,2 ]
Koch, Wolfgang F. [1 ,2 ]
Urbach, Carole [3 ]
Hollfelder, Florian [2 ]
Jermutus, Lutz [1 ]
机构
[1] AstraZeneca, Res & Early Dev, Cardiovasc Renal & Metab, BioPharmaceut R&D, Cambridge, England
[2] Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge, England
[3] AstraZeneca, R&D, Biol Engn, Cambridge, England
基金
欧盟地平线“2020”;
关键词
Protease; Proteolytic activation; Zymogen; Cytokine; Antibody engineering; Therapeutic antibodies; Activatable therapeutics; MATRIX-METALLOPROTEINASE INHIBITORS; COMPLEMENT THERAPEUTICS; PEPTIDE INHIBITOR; CANCER-THERAPY; FUSION PROTEIN; IN-VIVO; ANTIBODY; BINDING; SAFETY; PERIODONTITIS;
D O I
10.1016/j.drudis.2022.03.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Proteases have crucial roles in homeostasis and disease; and protease inhibitors and recombinant proteases in enzyme replacement therapy have become key therapeutic applications of protease biology across several indications. This review briefly summarises therapeutic approaches based on protease activation and focuses on how recent insights into the spatial and temporal control of the proteolytic activation of growth factors and interleukins are leading to unique strategies for the discovery of new medicines. In particular, two emerging areas are covered: the first is based on antibody therapies that target the process of proteolytic activation of the pro-form of proteins rather than their mature form; the second covers a potentially new class of biopharmaceuticals using engineered, proteolytically activable and initially inactive pro-forms of antibodies or effector proteins to increase specificity and improve the therapeutic window.
引用
收藏
页码:1743 / 1754
页数:12
相关论文
共 123 条
[51]  
Johnson ML, 2020, J CLIN ONCOL, V38
[52]   Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates [J].
Kajikawa, Tetsuhiro ;
Briones, Ruel A. ;
Resuello, Ranillo R. G. ;
Tuplano, Joel V. ;
Reis, Edimara S. ;
Hajishengallis, Evlambia ;
Garcia, Cristina A. G. ;
Yancopoulou, Despina ;
Lambris, John D. ;
Hajishengallis, George .
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2017, 6 :207-215
[53]   First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti-PD-L1 Probody [J].
de Ruijter, Laura Kist ;
Hooiveld-Noeken, Jahlisa S. ;
Giesen, Danique ;
Lub-de Hooge, Marjolijn N. ;
Kok, Iris C. ;
Brouwers, Adrienne H. ;
Elias, Sjoerd G. ;
Nguyen, Margaret T. L. ;
Lu, Hong ;
Gietema, Jourik A. ;
Jalving, Mathilde ;
de Groot, Derk J. A. ;
Vasiljeva, Olga ;
de Vries, Elisabeth G. E. .
CLINICAL CANCER RESEARCH, 2021, 27 (19) :5325-5333
[54]   ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models [J].
Li, Yingchun ;
Hickson, Jonathan A. ;
Ambrosi, Dominic J. ;
Haasch, Deanna L. ;
Foster-Duke, Kelly D. ;
Eaton, Lucia J. ;
DiGiammarino, Enrico L. ;
Panchal, Sanjay C. ;
Jiang, Fang ;
Mudd, Sarah R. ;
Zhang, Catherine ;
Akella, Surekha S. ;
Gao, Wenqing ;
Ralston, Sherry L. ;
Naumovski, Louie ;
Gu, Jijie ;
Morgan-Lappe, Susan E. .
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (05) :1039-1050
[55]   Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration A Randomized Phase 2 Trial [J].
Liao, David S. ;
Grossi, Federico, V ;
El Mehdi, Delphine ;
Gerber, Monica R. ;
Brown, David M. ;
Heier, Jeffrey S. ;
Wykoff, Charles C. ;
Singerman, Lawrence J. ;
Abraham, Prema ;
Grassmann, Felix ;
Nuernberg, Peter ;
Weber, Bernhard H. F. ;
Deschatelets, Pascal ;
Kim, Robert Y. ;
Chung, Carol Y. ;
Ribeiro, Ramiro M. ;
Hamdani, Mohamed ;
Rosenfeld, Philip J. ;
Boyer, David S. ;
Slakter, Jason S. ;
Francois, Cedric G. .
OPHTHALMOLOGY, 2020, 127 (02) :186-195
[56]   HPN601 IS A PROTEASE-ACTIVATED EPCAM-TARGETING T CELL ENGAGER WITH AN IMPROVED SAFETY PROFILE FOR THE TREATMENT OF SOLID TUMORS [J].
Lin, Jack ;
Rocha, Sony ;
Kwant, Kathryn ;
Dayao, Maria ;
Ng, Tessie ;
Aaron, Wade ;
Callihan, Evan ;
Gamez-Guerrero, Maria ;
Hemmati, Golzar ;
Wright, Kevin ;
Barath, Manasi ;
Xiao, Yinghua ;
Degree, Master ;
Yu, Timothy ;
Chew, Patrick ;
Evans, Thomas ;
O'Rear, Jessica ;
Gatto, Scott ;
Cremin, Michael ;
Yu, Stephen ;
Patnaik, Purbasa ;
Hundal, Avneel ;
Austin, Richard ;
Lemon, Bryan ;
Wesche, Holger .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 :A379-A379
[57]  
Lin SJ, 2021, CANCER RES, V81, P933, DOI DOI 10.1158/1538-7445.AM2021-933
[58]   Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria [J].
Lin, Zhuoer ;
Schmidt, Christoph Q. ;
Koutsogiannaki, Sophia ;
Ricci, Patrizia ;
Risitano, Antonio M. ;
Lambris, John D. ;
Ricklin, Daniel .
BLOOD, 2015, 126 (07) :891-894
[59]  
Liu G, 2021, ABSTRACT 1853 NOV S, V81, P1853
[60]   Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy [J].
Long, Kimberly K. ;
O'Shea, Karen M. ;
Khairallah, Ramzi J. ;
Howell, Kelly ;
Paushkin, Sergey ;
Chen, Karen S. ;
Cote, Shaun M. ;
Webster, Micah T. ;
Stains, Joseph P. ;
Treece, Erin ;
Buckler, Alan ;
Donovan, Adriana .
HUMAN MOLECULAR GENETICS, 2019, 28 (07) :1076-1089